BR112016001395A8 - forma de dosagem unitária oral sólida de metaxalona - Google Patents

forma de dosagem unitária oral sólida de metaxalona Download PDF

Info

Publication number
BR112016001395A8
BR112016001395A8 BR112016001395A BR112016001395A BR112016001395A8 BR 112016001395 A8 BR112016001395 A8 BR 112016001395A8 BR 112016001395 A BR112016001395 A BR 112016001395A BR 112016001395 A BR112016001395 A BR 112016001395A BR 112016001395 A8 BR112016001395 A8 BR 112016001395A8
Authority
BR
Brazil
Prior art keywords
metaxalone
dosage form
unit dosage
solid oral
oral unit
Prior art date
Application number
BR112016001395A
Other languages
English (en)
Other versions
BR112016001395A2 (pt
Inventor
H William Bosch
Original Assignee
Iceutica Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Iceutica Inc filed Critical Iceutica Inc
Publication of BR112016001395A2 publication Critical patent/BR112016001395A2/pt
Publication of BR112016001395A8 publication Critical patent/BR112016001395A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/24—Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

formas de dosagem de partículas submicrônicas contendo metaxalona de metaxalona e usos das mesmas são descritas. as for-mas de dosagem submicrônicas têm biodisponibilidade melhorada em comparação com certas formas de dosagem de metaxalona convencionais.
BR112016001395A 2013-07-22 2014-07-22 forma de dosagem unitária oral sólida de metaxalona BR112016001395A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361857199P 2013-07-22 2013-07-22
PCT/US2014/047701 WO2015013336A1 (en) 2013-07-22 2014-07-22 Formulation of metaxalone

Publications (2)

Publication Number Publication Date
BR112016001395A2 BR112016001395A2 (pt) 2017-07-25
BR112016001395A8 true BR112016001395A8 (pt) 2020-01-14

Family

ID=52393794

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016001395A BR112016001395A8 (pt) 2013-07-22 2014-07-22 forma de dosagem unitária oral sólida de metaxalona

Country Status (18)

Country Link
US (6) US20160159756A1 (pt)
EP (1) EP3024440B1 (pt)
JP (1) JP6453876B2 (pt)
KR (1) KR20160039608A (pt)
CN (1) CN105431136B (pt)
AU (1) AU2014293193A1 (pt)
BR (1) BR112016001395A8 (pt)
CA (1) CA2918908A1 (pt)
CL (1) CL2016000171A1 (pt)
DK (1) DK3024440T3 (pt)
HK (2) HK1222570A1 (pt)
IL (1) IL243447A0 (pt)
MX (1) MX365591B (pt)
MY (1) MY181226A (pt)
RU (1) RU2684914C2 (pt)
SG (2) SG10201800491RA (pt)
WO (1) WO2015013336A1 (pt)
ZA (1) ZA201600408B (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9526734B2 (en) 2014-06-09 2016-12-27 Iceutica Pty Ltd. Formulation of meloxicam
US20200405693A1 (en) * 2019-06-25 2020-12-31 Primus Pharmaceuticals, Inc. Reduced dose metaxalone formulations

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478705A (en) 1994-05-25 1995-12-26 Eastman Kodak Company Milling a compound useful in imaging elements using polymeric milling media
US5500331A (en) 1994-05-25 1996-03-19 Eastman Kodak Company Comminution with small particle milling media
US7714006B1 (en) * 2001-12-03 2010-05-11 King Pharmaceuticals Research & Development, Inc. Methods of modifying the bioavailability of metaxalone
US6407128B1 (en) * 2001-12-03 2002-06-18 Elan Pharmaceuticals, Inc. Method for increasing the bioavailability of metaxalone
WO2004019937A1 (en) * 2002-09-02 2004-03-11 Sun Pharmaceutical Industries Limited Pharmaceutical composition of metaxalone with enhanced oral bioavailability
DE602004018150D1 (de) * 2003-08-08 2009-01-15 Elan Pharma Int Ltd Neue metaxalon-zusammensetzungen
CA2563739C (en) * 2004-03-08 2013-07-09 Spiridon Spireas Bioavailable solid dosage forms of metaxalone
US20120093928A1 (en) * 2007-08-09 2012-04-19 Ranbaxy Laboratories Limited Oral metaxalone compositions
EP2421530B1 (en) * 2009-04-24 2019-08-21 Iceutica Pty Ltd. Formulation of metaxalone
MY159098A (en) * 2009-04-24 2016-12-15 Iceutica Pty Ltd Production of encapsulated nanoparticles at high volume fractions
RU2499595C1 (ru) * 2012-07-03 2013-11-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Воронежская государственная медицинская академия им. Н.Н. Бурденко" Министерства здравоохранения и социального развития Российской Федерации Способ повышения качества жизни и улучшения способностей к выполнению профессиональной деятельности у пациентов с остеоартрозом, выполняющих водительские и диспетчерско-операторские функции

Also Published As

Publication number Publication date
RU2016105763A (ru) 2017-08-29
IL243447A0 (en) 2016-02-29
US20160159756A1 (en) 2016-06-09
EP3024440B1 (en) 2018-11-28
RU2016105763A3 (pt) 2018-06-13
HK1225301A1 (zh) 2017-09-08
US20180148422A1 (en) 2018-05-31
MX2016001019A (es) 2016-07-19
EP3024440A4 (en) 2017-01-25
WO2015013336A1 (en) 2015-01-29
MX365591B (es) 2019-06-07
ZA201600408B (en) 2017-04-26
US20220235017A1 (en) 2022-07-28
US20190152930A1 (en) 2019-05-23
DK3024440T3 (en) 2019-03-11
EP3024440A1 (en) 2016-06-01
CN105431136B (zh) 2020-03-24
AU2014293193A1 (en) 2016-01-28
KR20160039608A (ko) 2016-04-11
CN105431136A (zh) 2016-03-23
MY181226A (en) 2020-12-21
US20210101873A1 (en) 2021-04-08
SG10201800491RA (en) 2018-03-28
US20240150304A1 (en) 2024-05-09
CA2918908A1 (en) 2015-01-29
JP6453876B2 (ja) 2019-01-16
RU2684914C2 (ru) 2019-04-16
BR112016001395A2 (pt) 2017-07-25
HK1222570A1 (zh) 2017-07-07
SG11201600264TA (en) 2016-02-26
JP2016527251A (ja) 2016-09-08
CL2016000171A1 (es) 2016-07-01

Similar Documents

Publication Publication Date Title
CY1120730T1 (el) Απο του στοματος χορηγουμενη δοσολογια ενωσεων glp-1
CY1124436T1 (el) Δικυκλικες ετεροκυκλικες ενωσεις και χρησεις αυτων στη θεραπεια
PH12019500176A1 (en) Heterocyclic compounds and ther uses
EA201591616A1 (ru) Трифторметил-замещенные аннелированные пиримидины и их применение
EA201591524A1 (ru) Производные 2-аминопиримидина для лечения вирусных инфекций
EA201591887A1 (ru) Макроциклические деазаоксипурины для лечения вирусных инфекций
EA201500314A1 (ru) Лекарственные формы энзалутамида
EA201992133A1 (ru) Производные пиперидино-пиримидина для лечения вирусных инфекций
CY1120204T1 (el) Αμορφη στερεα διασπορα για χρηση σε θεραπεια καρκινου του εγκεφαλο
EA201591712A1 (ru) Антибиотические композиции на основе цефтолозана
MX2015012416A (es) Compuestos heterociclicos y sus usos.
FI20135866L (fi) Mikrobiologinen keratiinin prosessointi
UY34829A (es) Nueva dosificación y formulación
MX2016006087A (es) Formulaciones de desintegracion rapida y metodos de uso.
CY1123284T1 (el) Συνθεση που περιλαμβανει υδροκορτιζονη
PH12017500923A1 (en) New dosage and use of a a2a antagonist
EA201500927A1 (ru) Твердые липидные наночастицы (i)
BR112016001395A8 (pt) forma de dosagem unitária oral sólida de metaxalona
MX2020006075A (es) Composiciones farmaceuticas de bendamustina.
FI20136136A (fi) Menetelmä kosmeettisten koostumusten valmistamiseksi, kosmeettiset koostumukset sekä niiden käyttö
CY1119212T1 (el) Χρηση του odiparcil στη θεραπεια μιας μυκοπολυσακχαριδωσης
FR3007654B1 (fr) Composition de solute de rehydratation orale contenant des probiotiques
TH135430B (th) เก้าอี้
ITPD20130064U1 (it) Sistema di tipo "point of care" di misura della bilirubina totale nel plasma, in particolare di neonati
HUP1300025A2 (hu) Készítmény az UVB-fényterápia hatékonyságának fokozására, eljárás annak elõállítására és alkalmazása

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2680 DE 17-05-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.